Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Share This Webinar
About This Webinar
The Center for Biologics Evaluation & Research (CBER) within the U.S. Food & Drug Administration (FDA) regulates biological products for human use under applicable federal laws. CBER protects and advances the public health by ensuring that biological products are safe, effective, and available to those who need them. CBER's Office of Tissues and Advanced Therapies (OTAT) plans and conducts research related to the development, manufacture, and testing of cellular, tissue, gene therapy products, and plasma protein biologics and recombinant analogues.
Language:
English
Who can attend? Everyone
Featured Presenters
Principal Investigator
Pankaj Mandal is a Principal Investigator at CBER, FDA. He received his PhD in Veterinary Medicine from Ludwig Maximilian University, Munich in 2009. He joined Boston Children’s Hospital/Harvard Medical School for his postdoctoral research on cellular reprogramming, developed Hematopoietic Stem Cell (HSC)-specific reporter strains of mice, and evaluated the efficacy of CRISPR/Cas9 genome editing in human HSCs. He started his research group at CBER in 2019. His research work is focused on understanding HSC biology and advanced manufacturing of CRISPR-edited HSC-based therapeutics.
Hosted By
The full session archive, available exclusively for attendees of the American Society of Gene & Cell Therapy's 23rd Annual Meeting, May 12-15, 2020.
Documents